1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow IDO1 inhibitor INCB024360: new trials by email Literature Review of IDO1 inhibitor INCB024360 trials Research Report on IDO1 inhibitor INCB024360
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360 - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 | 2019-03-22 | 2020-07-02 |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 |
Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (1)
Kunle Odunsi (1) · Michael Lim, MD (1)
P30CA016056 (1)